Eikon Therapeutics

We are pleased to announce that Michael Klobuchar is joining Eikon Therapeutics as our new Chief Operating Officer! Mike joins Eikon from Merck & Co. Inc. where he spent more than 25 years in senior leadership roles across R&D, manufacturing, finance, and corporate strategy, most recently as Executive Vice President & Chief Strategy Officer. “Mike is an outstanding leader whose deep experience in navigating complex industrial strategies and his proven track record of operational excellence make him the ideal person to lead Eikon’s infrastructure development as we scale our efforts to bring transformative discovery technologies to scientists and innovative new therapies to patients,” said Eikon CEO & Board Chair Roger M. Perlmutter, M.D., Ph.D. At Eikon, we are dedicated to advancing our pioneering single-molecule tracking (SMT) platform to develop next-generation therapeutics. As we continue to scale and push the boundaries of what’s possible, Mike will play a pivotal role in driving our operational excellence and strategic growth, ensuring that Eikon remains at the forefront of scientific discovery and patient impact. Learn more here: https://lnkd.in/gxUbJ-KD Please join us in welcoming Mike to #TeamEikon!

We're excited to see this collaborative work from the Tim Mitchison and Pamela Silver labs at Harvard Medical School posted on biorXiv. At Eikon, we’ve seen how measuring the movement of proteins in the cell can be a powerful and versatile tool for drug discovery. By participating in Eikon's?Technology Access Program, Rui Tong Quek was able to measure protein-protein interactions with our single-molecule tracking (SMT) platform in support of her research on condensate formation. Eikon’s SMT platform permits us to assay protein motion in live cells by measuring the movement of millions of individual proteins. Using Eikon’s high-throughput platform, Rui measured the condensate formation of nucleocapsid (N) protein from SARS-CoV-2. Not only could she measure changes in N-protein motion upon GSK3 inhibition, but she could also see those changes starting to occur within an hour, well before any sort of condensates become visible. Check out the preprint or learn more:?https://lnkd.in/gJupmUys #DrugDiscovery #SingleMoleculeTracking #SMT?

Our team at Eikon Therapeutics is making waves in drug discovery by leveraging cutting-edge AI technologies.?Eikon Associate Director Adi Hanuka, PhD, recently presented how our advanced AI models are overcoming challenges in predicting drug absorption. By integrating public and proprietary data, our models are significantly improving prediction accuracy, leading to faster and more effective drug development. Excited about the future? We are too! Stay tuned for more groundbreaking advancements from our talented team. #TeamEikon #AI #DrugDiscovery #BiotechInnovation

At Eikon Therapeutics, our Clinical team plays a vital role in translating groundbreaking discoveries into life-changing medicines for patients with unmet needs, including cancer and neurodegenerative diseases. With a commitment to patient-centered clinical excellence, we prioritize the well-being of participants in our clinical trials and strive to deliver high-quality data that supports the development of effective therapies. Our track record showcases our integrated capabilities to advance both in-licensed assets and those emerging from our proprietary platform. As part of #TeamEikon, you'll contribute to a vision that redefines the boundaries of science, driving innovation that has the potential to transform the lives of patients around the world. Explore West- and East-Coast opportunities to join our clinical team here: https://lnkd.in/g7V6b9RZ #ClinicalResearch #HealthcareInnovation #ScienceCareers

Navigating the complexities of clinical trial supply chains is more challenging than ever as the industry adapts to new technologies and ever-changing global regulations. On September 17, Eikon Therapeutics’ Senior Director of Clinical Supply Chain Reid Tonik will share insights on “Creating a Clinical Supply Chain Playbook for Onboarding Acquired Assets” at Clinical Trial Supply West Coast in San Francisco. Reid will cover best practices and actionable strategies including: ? Identifying priorities and guiding transition activities while mitigating risks to patient dosing and trial continuity in a culturally and personally mindful way. ? Deciding when and what to integrate, and assessing the impact on the acquired portfolio. ? Tools of the trade and lessons learned from past mistakes. We hope to see you there! ? #TeamEikon #ClinicalTrials?#ClinicalOperations #CTSWestCoast

We’re so proud of #TeamEikon for how they support and give back to our communities! Eikon’s Veterans Employee Resource Group (ERG) includes 11 veterans, military spouses, and military supporters. This recent partnership with Operation Homefront is the first of many events planned in the coming months where the group will be volunteering and showing support for our local military community.

We’re looking forward to the Morgan Stanley 22nd?Annual Global Healthcare Conference on Sept. 4th in New York City. Eikon Therapeutics’ CEO?Roger M. Perlmutter?and CFO?Alfred (Freddie) Bowie?will present a business update on the company’s progress including recent advancements in the company’s pipeline and clinical development programs, as well as updates related to our Eikon Systems business. To access the archived recording after the event, visit the link in comments.?

"I’m excited about the prospect that new technological advances have afforded us to further accelerate innovative therapeutic development.” Ten years after playing an instrumental role in bringing Keytruda —one of the most impactful cancer therapies in history— to market, Roy Baynes, MD, PhD, now serves as?Eikon?Therapeutics' Chief Medical Officer. At?Eikon, Roy is building one of the industry's most sophisticated clinical organizations and a therapeutic pipeline with the potential to deliver important new medicines to address serious illnesses?that reflect areas of unmet?medical need. In a recent podcast interview, Roy shared insights from his accomplished career and discussed what excites him most about the future of medicine, particularly the potential of new technologies and artificial intelligence. Catch the full interview and explore current opportunities to join Roy's growing clinical team at?Eikon?(links in comments). #TeamEikon #Biotech

We're looking forward to next week's Goldman Sachs Global Healthcare Conference, where our CEO, Roger M. Perlmutter, and CFO, Alfred (Freddie) Bowie, will be providing important business updates and highlighting the exciting progress of our lead clinical programs, along with key data presented at the recent #AACR24 and #ASCO24 meetings. To learn more and access an archived recording of the presentation, please visit: www.EikonTx.com/news. #TeamEikon #Biotech

If you’re keen to learn more about Eikon's progress over recent months, check us out at ASCO (and link below), follow on LinkedIn or leave a comment. #eikontx #science #engineering #therapeutics